TP53 and carcinoma: Further genetic alterations which have been described in more advanced tumours include targets of MSI (BAX, TGFßR2, IGFR2, p53, often present late during adenoma/carcinoma progression), CDKN2A/p16, MINT genes, 3p, and 15q (CRAC1) [10, 33, 44].